Just as the Phantom orchestrates events from the shadows of the Paris Opera House, innate lymphoid cells (ILC) operate behind the scenes of the immune system, shaping immune responses without the antigen specificity of their T cell counterparts. While more understudied than their better-known T cell counterparts, these enigmatic cells serve as first responders to infection and tissue disruption, playing crucial roles in mucosal immunity and homeostasis—packing an iron-fist punch under a velvet glove. However, in the context of inborn errors of immunity (IEI)—a diverse group of over 500 monogenic disorders affecting immune function—the role of ILC remains largely unmasked. While traditionally overlooked, recent patient studies reveal that ILC dysfunction contributes to disease pathogenesis in at least 19 distinct IEI, raising critical questions: Are ILC indispensable protectors, or do they represent a redundant act within the immune repertoire? How do they respond to standard treatments such as hematopoietic stem cell transplantation (HSCT)? In this review, we unveil the hidden roles of ILC in IEI, analyzing their developmental and functional defects, their role in immune dysregulation, and their therapeutic potential. Much like the Phantom’s elusive presence, ILC may hold the key to understanding immune resilience and designing novel treatments for immunocompromised patients.
Objective and design: In this report, we identified a novel hemizygous ELF4 variant (c.1822G > C; p.Gly608Arg) in an adolescent male with chronic immune thrombocytopenia (ITP) and performed functional immunologic characterization. Materials and methods: Peripheral blood mononuclear cells (PBMCs) of the patient and age-matched controls were characterized by flow cytometry with respect to T cell phenotype, activation, proliferation and NK cell cytotoxicity. Results: The p.Gly608Arg substitution affects a highly conserved residue in the C-terminal regulatory domain of ELF4 and is predicted to be damaging. Immunophenotyping showed an expanded CD8 + T-cell compartment, an inverted CD4/CD8 ratio, reduced naïve T-cell populations, and accelerated acquisition of memory-like phenotypes upon activation. Both CD4 + and CD8 + T cells displayed increased proliferation following TCR stimulation, consistent with impaired ELF4 -dependent regulation of effector T-cell expansion. NK cells exhibited reduced granzyme B and perforin expression and markedly diminished cytotoxicity against K562 targets, indicating defects in maturation and effector function. Conclusions: These findings suggest that the identified ELF4 variant is associated with combined T- and NK-cell dysfunction. This case expands the clinical spectrum of Deficiency in ELF4 , X-linked and underscores the relevance of evaluating ELF4 mutations in patients with unexplained cytopenias accompanied by dysregulated lymphocyte activation and impaired cytotoxic responses.
Purpose: Hyper-IgM syndromes (HIGM) are primary immunodeficiencies characterized by defective class-switch recombination (CSR) and impaired humoral immunity. While genetic causes such as CD40L and AICDA mutations are well established, a detailed comparison of B cell maturation dynamics across HIGM subtypes remains limited. To comprehensively characterize B cell immunophenotypes and functional responses in patients with HIGM and to delineate mutation-specific differences in B cell maturation and proliferation. Method: Four patients with genetically confirmed HIGM (one CD40L and three homozygous AICDA mutations, c.70C>T; p.R24W) and age- and sex-matched healthy controls were studied. Peripheral blood mononuclear cells were analyzed by multiparameter flow cytometry to define B cell subsets based on CD19, CD20, CD24, CD27, CD38, IgD, and IgM expression. B cell proliferation was assessed following CpG stimulation. Results: All patients exhibited a marked reduction of class-switched memory B cells (CD27⁺IgD⁻) and accumulation of naive B cells (CD27⁻IgD⁺), consistent with defective CSR. The CD40L -deficient patient demonstrated profound depletion of plasmablasts and precursor skewing, reflecting failure of germinal center formation. In contrast, AID patients showed preserved CD27 expression with variable expansion of transitional and plasmablast populations, suggesting intact T cell–dependent activation but intrinsic failure of CSR. Functional assays revealed heterogeneous proliferative responses in CD40L deficiency and AICDA -deficient patient, but impaired proliferation in another AICDA -deficient individual, highlighting inter-individual variability. Conclusion: Detailed immunophenotyping reveals distinct B cell maturation arrest points in CD40L - versus AICDA -associated HIGM. Flow cytometric analysis of B cell subsets provides valuable insights into disease mechanisms, supports differential diagnosis, and may inform clinical monitoring and therapeutic decision-making in HIGM.
Background: Isocitrate dehydrogenase 1 (IDH1) mutations confer distinct biological properties to gliomas, including the reshaping of the tumor immune microenvironment. While T cell dysfunction in glioblastoma has been extensively characterized, the role of innate lymphoid cells (ILCs)-critical regulators of tissue homeostasis and early immune responses- remains poorly understood. Methods: We investigated how IDH1 mutations and their oncometabolite D-2-hydroxyglutarate (D-2HG) influence ILC subset distribution, immune checkpoint expression, and cytokine production in glioma patients, glioma-conditioned medium (GCM) models, and in vivo mouse experiments. Tumor and peripheral blood samples from 32 glioma patients (WHO 2021 classification, grades II–IV) were analyzed by flow cytometry to assess ILC subsets and immunecheckpoint molecules (PD-1, CTLA-4, KLRG1). Tonsil-derived human ILCs were co-cultured with IDH1-mutant or wild-type glioma cells and their GCM. In vitro, ILCs were exposed to graded concentrations of D-2HG, whereas in vivo studies involved intraperitoneal administration of D-2HG or L-2HG in mice to evaluate ILC distribution across lymphoid and mucosal tissues. Results: IDH1-mutant gliomas exhibited increased ILC3 and decreased ILC1 frequencies in both tumor tissue and peripheral blood. ILC3s in IDH1-mutant tumors expressed higher PD-1, whereas ILC2s showed reduced PD-1 levels. In co-culture assays, IDH1-mutant glioma cells and their GCM suppressed PD-1 and CTLA-4 expression on ILCs while promoting proliferation. Exposure to D-2HG recapitulated these effects in a dose-dependent manner, reducing checkpoint expression and enhancing IFN-γ and TNF-α secretion. In vivo, D-2HG and L-2HG differentially altered ILC subset distribution across mucosal and lymphoid compartments. Conclusions: IDH1 mutations and their associated oncometabolite D-2HG remodel the innate lymphoid cell landscape in gliomas, driving an ILC3-biased phenotype with reduced checkpoint receptor expression. These findings identify ILCs as key modulators of glioma immunity and suggest that targeting innate immune pathways could complement existing immunotherapeutic approaches.